Lupus Nephritis - Pipeline Review, H2 2016

  • ID: 3939692
  • Report
  • 142 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Invion Limited
  • MedImmune, LLC
  • Ra Pharmaceuticals, Inc.
  • MORE
Lupus Nephritis - Pipeline Review, H2 2016

Summary

‘Lupus Nephritis - Pipeline Review, H2 2016’, provides an overview of the Lupus Nephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
- The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lupus Nephritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Invion Limited
  • MedImmune, LLC
  • Ra Pharmaceuticals, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Lupus Nephritis Overview

Therapeutics Development

Pipeline Products for Lupus Nephritis - Overview

Pipeline Products for Lupus Nephritis - Comparative Analysis

Lupus Nephritis - Therapeutics under Development by Companies

Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes

Lupus Nephritis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Lupus Nephritis - Products under Development by Companies

Lupus Nephritis - Products under Investigation by Universities/Institutes

Lupus Nephritis - Companies Involved in Therapeutics Development

AbbVie Inc

Asahi Kasei Pharma Corp.

Astellas Pharma Inc.

Aurinia Pharmaceuticals Inc

Azano Pharmaceuticals Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Deltanoid Pharmaceuticals Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

HanAll Biopharma Co., Ltd.

Invion Limited

KPI Therapeutics, Inc.

MedImmune, LLC

Omeros Corporation

Ra Pharmaceuticals, Inc.

Resolve Therapeutics, LLC

Takeda Pharmaceutical Company Limited

TxCell SA

Lupus Nephritis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anifrolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-655064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986147 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENTX-DN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixazomib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mizoribine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Lupus Nephritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obinutuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-721 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-Dex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5461111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSLV-145 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

venetoclax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voclosporin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Y-175L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lupus Nephritis - Dormant Projects

Lupus Nephritis - Discontinued Products

Lupus Nephritis - Product Development Milestones

Featured News & Press Releases

Aug 15, 2016: Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis

Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)

Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus

May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus

May 12, 2016: Aurinia Announces Presentations at the European Renal Association - European Dialysis and Transplant Association Meeting

May 09, 2016: Aurinia Initiates First Clinical Study of Voclosporin for Japan

Apr 20, 2016: Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases

Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned

Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis

Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis

Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer

Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis

Dec 03, 2015: Ocata’s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis

Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned

Nov 10, 2015: Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Lupus Nephritis, H2 2016

Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2016

Lupus Nephritis - Pipeline by AbbVie Inc, H2 2016

Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H2 2016

Lupus Nephritis - Pipeline by Astellas Pharma Inc., H2 2016

Lupus Nephritis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016

Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2016

Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2016

Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016

Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H2 2016

Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016

Lupus Nephritis - Pipeline by Invion Limited, H2 2016

Lupus Nephritis - Pipeline by KPI Therapeutics, Inc., H2 2016

Lupus Nephritis - Pipeline by MedImmune, LLC, H2 2016

Lupus Nephritis - Pipeline by Omeros Corporation, H2 2016

Lupus Nephritis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016

Lupus Nephritis - Pipeline by Resolve Therapeutics, LLC, H2 2016

Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Lupus Nephritis - Pipeline by TxCell SA, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Lupus Nephritis - Dormant Projects, H2 2016

Lupus Nephritis - Dormant Projects (Contd..1), H2 2016

Lupus Nephritis - Discontinued Products, H2 2016 126List of Figures

Number of Products under Development for Lupus Nephritis, H2 2016

Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc.
  • F. Hoffmann-La Roche Ltd.
  • Invion Limited
  • MedImmune, LLC
  • Ra Pharmaceuticals, Inc.
  • MORE
Lupus Nephritis Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. Symptoms include weight gain, high blood pressure, dark urine and foamy, frothy urine. Treatment includes corticosteroids, immunosuppressive drugs and health lifestyle.

Lupus Nephritis pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Our latest report Lupus Nephritis – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Aurinia Pharmaceuticals Inc
Azano Pharmaceuticals Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Deltanoid Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
Invion Limited
KPI Therapeutics, Inc.
MedImmune, LLC
Omeros Corporation
Ra Pharmaceuticals, Inc.
Resolve Therapeutics, LLC
Takeda Pharmaceutical Company Limited
TxCell SA
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll